Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19 - Tisch, C.; Xourgia, E.; Exadaktylos, A.; Ziaka, M. (Endocrine, 2024)
OBJECTIVE: SGLT-2i are increasingly recognized for their benefits in patients with cardiometabolic risk factors. Additionally, emerging evidence suggests potential applications in acute illnesses, including COVID-19. This systematic review aims to evaluate the effects of SGLT-2i in patients facing acute illness, particularly focusing on SARS-CoV-2 infection. METHODS: Following PRISMA guidelines, a systematic search of PubMed, Scopus, medRxiv, Research Square, and Google Scholar identified 22 studies meeting inclusion criteria, including randomized controlled trials and observational studies. Data extraction and quality assessment were conducted independently. RESULTS: Out of the 22 studies included in the review, six reported reduced mortality in DM-2 patients taking SGLT-2i, while two found a decreased risk of hospitalization. Moreover, one study demonstrated a lower in-hospital mortality rate in DM-2 patients under combined therapy of metformin plus SGLT-2i. However, three studies showed a neutral effect on the risk of hospitalization. No increased risk of developing COVID-19 was associated with SGLT-2i use in DM-2 patients. Prior use of SGLT-2i was not associated with ICU admission and need for MV. The risk of acute kidney injury showed variability, with inconsistent evidence regarding diabetic ketoacidosis. CONCLUSION: Our systematic review reveals mixed findings on the efficacy of SGLT-2i use in COVID-19 patients with cardiometabolic risk factors. While some studies suggest potential benefits in reducing mortality and hospitalizations, others report inconclusive results. Further research is needed to clarify optimal usage and mitigate associated risks, emphasizing caution in clinical interpretation.
Keywords: journalArticle; *COVID-19/mortality/complications/epidemiology; *Diabetes Mellitus, Type 2/drug therapy/complications; *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use; Acute Disease; Acute Illness; Acute Kidney Injury; COVID-19 Drug Treatment; Covid-19; Diabetic Ketoacidosis; Hospitalization/statistics & numerical data; Humans; Intensive Care Unit; Mechanical Ventilation; SARS-CoV-2; SGLT-2 Inhibitors